FGFR2 and cholangiocarcinoma: In a phase II trial, the authors demonstrated the efficacy and benefits of pemigatinib, a FGFR1, FGFR2 and FGFR3 inhibitor, in treating advanced CCA with FGFR2 mutations [36].